Welcome to our dedicated page for Cytodyn news (Ticker: CYDY), a resource for investors and traders seeking the latest updates and insights on Cytodyn stock.
CytoDyn Inc (CYDY) is a clinical-stage biotechnology company advancing leronlimab, an investigational CCR5-targeting therapy with applications in oncology, inflammation, and infectious diseases. This dedicated news hub provides investors and researchers with essential updates on clinical developments, regulatory milestones, and strategic partnerships.
Our curated collection features official press releases and verified news covering clinical trial results, FDA communications, and research collaborations. Users gain access to critical updates about leronlimab's development across multiple therapeutic areas, including ongoing studies in metastatic cancers and inflammatory conditions.
The resource emphasizes CytoDyn's progress in resolving historical challenges and establishing robust clinical protocols. Key content categories include trial design updates, partner announcements with organizations like Syneos Health, and regulatory pathway developments. All materials maintain strict adherence to factual reporting standards.
For those monitoring biopharmaceutical innovation, this page serves as a reliable source for tracking CytoDyn's evidence-based approach to drug development. Bookmark this hub to stay informed about new developments in CCR5-targeted therapies and the company's evolving clinical pipeline.
CytoDyn Inc. (OTCQB: CYDY) announced an upcoming webcast for the investment community scheduled on April 11, 2023, at 1:00 PM PT / 4:00 PM ET. The update will feature key executives, including Board Chair Tanya Urbach and President Cyrus Arman, discussing the company’s progress and the potential of leronlimab, a CCR5 antagonist. Questions can be submitted prior to the event until Noon PT on April 7, 2023, and will be addressed during the presentation if appropriate. A replay will be available approximately one hour after the event until May 11, 2023.
CytoDyn Inc. (OTCQB: CYDY) will hold a webcast on December 29, 2022, at 8:00 a.m. PT to discuss the performance of its investigational drug, leronlimab, in clinical trials. The discussion will also address recent charges against former CEO Nader Pourhassan, who was terminated on January 24, 2022, and has since had no association with the company. CytoDyn is focused on developing leronlimab for various therapeutic applications, including infectious diseases, cancer, and autoimmune conditions. The webcast replay will be available until January 29, 2023.
CytoDyn Inc. (OTCQB: CYDY) will host a virtual R&D Update on December 7, 2022, at 11:00 a.m. ET. The event will feature presentations by key management and Scientific Advisory Board members discussing the clinical development of leronlimab, a CCR5 antagonist. Presenters include Cyrus Arman, M.D., who will overview the R&D strategy; Mazen Noureddin, M.D., discussing leronlimab's potential in treating NASH; Stefan Glück, M.D., focused on cancer therapy; and Jonah Sacha, Ph.D., on HIV research. The event can be accessed via the company's website.
CytoDyn (OTCQB: CYDY) announced the voluntary withdrawal of its Biologics License Application (BLA) for leronlimab, aimed at treating HIV-MDR patients. The decision stems from concerns over data quality from a clinical research organization (CRO). Despite meeting primary endpoints in trials, the company believes FDA approval is unlikely without substantial investments. CytoDyn plans to respond to a clinical hold and continue exploring leronlimab's effectiveness in other areas, including NASH and oncology, where promising results have been observed. A webcast will provide further updates on these developments.
